KEGG   DRUG: Talquetamab
Entry
D12180                      Drug                                   
Name
Talquetamab (USAN/INN);
Talquetamab (genetical recombination) (JAN);
Talquetamab-tgvs;
Talvey (TN)
Product
Formula
C6410H9938N1716O2006S45
Exact mass
144489.5821
Mol weight
144578.80
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL INPYNSDTNY
AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARVA LRVALDYWGQ GTLVTVSSAS
TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EAAGGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV
FSCSVMHEAL HNHYTQKSLS LSLGK
(heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR IRSKYNNYAT
YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR HGNFGNSYVS WFAYWGQGTL
VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT SKAKGQPRE PQVYTLPPSQ
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFL LYSKLTVDKS
RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS ASYRYSGVPS
RFSGSGSGTE FTLTISNLQP EDFATYYCQQ YNRYPYTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(light chain)
QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI GGTNKRAPGT
PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF GGGTKLTVLG QPKAAPSVTL
FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
(Disulfide bridge: H22-H96, H132-L214, H145-H201, H224-h231, H227-h234, H259-H319, H365-H423, h22-h98, h139-l214, h152-h208, h266-h326, h372-h430, L23-L88, L134-L194, l22-l90, l137-l196)
  Type
Peptide
Remark
ATC code: L01FX29
Product: D12180<US>
Efficacy
Antineoplastic
  Disease
Multiple myeloma [DS:H00010]
  Type
Monoclonal antibody, bispecific antibody
Comment
Treatment of multiple myeloma
Target
GPRC5D [HSA:55507] [KO:K04621]
CD3E [HSA:916] [KO:K06451]
  Pathway
hsa04640  Hematopoietic cell lineage
hsa04660  T cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX29 Talquetamab
      D12180  Talquetamab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-CD3/GPRC5D Antibodies
    Talquetamab
     D12180  Talquetamab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 G Protein-coupled receptors
  Metabotropic glutamate receptor family
   Orphan GPRC5
    GPRC5D
     D12180  Talquetamab (USAN/INN) <US>
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3E
     D12180  Talquetamab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12180
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12180
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12180
Other DBs
CAS: 2226212-40-2
PubChem: 497620593
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system